Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care

Eur Respir J. 2022 Dec 8;60(6):2201690. doi: 10.1183/13993003.01690-2022. Print 2022 Dec.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Drug Monitoring*
  • Humans
  • Medication Adherence
  • Technology
  • Tuberculosis* / drug therapy

Substances

  • Antitubercular Agents